Abstracts Archive - Page 1089 of 2607 - ACR Meeting Abstracts

Abstract Number: 2234 • 2019 ACR/ARP Annual Meeting
Osteoporosis Screening in a Resident-Driven Clinic of a Large Academic Hospital
Anam Umar¹, Titilope Olanipenkun ¹, Hiu Sze Kwong ¹, Chelsy Harris ¹, Amber Faquih ², Muhammad Bilal ¹ and Chinedu Ivonye ¹, ¹Morehouse School Of Medicine, Atlanta, ²Emory University School Of Medicine, atlanta
Background/Purpose: Osteoporosis is associated with fragility fractures and represents a significant public health problem. The United States Preventive Services Task Forces (USPSTF) recommend dual-energy x-ray…
Abstract Number: 2235 • 2019 ACR/ARP Annual Meeting
Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough?
Anam Umar¹, Eric Chang ¹, Martin Campbell ¹, Hiu Sze Kwong ¹, Elyse Steven ¹, Amber Faquih ², Muhammad Bilal ¹ and Ivonye Chinedu ¹, ¹Morehouse School Of Medicine, Atlanta, ²Emory University School Of Medicine, atlanta
Background/Purpose: Osteoporosis is a well-known extra-articular complication in rheumatoid arthritis (RA) patients It is more common in patients with RA than in the general population,…
Abstract Number: 2236 • 2019 ACR/ARP Annual Meeting
Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
Jasmin Ma¹, Jon Collins ², Eileen Davidson ², Kelly English ³, Alison Hoens ⁴, Karen Tsui ⁵, Shanon McQuitty ², Louella Sequeira ³ and Linda Li ⁴, ¹Arthritis Research Canada/University of British Columbia, Vancouver, Canada, ²Arthritis Research Canada, Richmond, Canada, ³Arthritis Research Canada, Richmond, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Patient Advisory Board, Toronto, ON, Canada
Background/Purpose: Strength training (ST) rates in people with rheumatoid arthritis (RA) are remarkably low (1-14%), reducing the potential health benefits of ST for this population…
Abstract Number: 2237 • 2019 ACR/ARP Annual Meeting
Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
Isabela Bertoglio¹, Glaucia Abrahão ², Michelle Remião Ugolini-Lopes ³, Fernando Henrique Souza ⁴, Renata Miossi ⁴, Samuel Shinjo ⁵ and Eloisa Bonfa ⁶, ¹Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Sao Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil, ³Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Univeristy Of Sao Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Treat-to-target (T2T) strategy has become the best approach to treat several rheumatic disorders. However, most targets are only based on specialists’ opinions, which may…
Abstract Number: 2238 • 2019 ACR/ARP Annual Meeting
Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) to remission optimally ensures control of symptoms, prevention of structural damage, optimization of function and quality of life. Adherence…
Abstract Number: 2239 • 2019 ACR/ARP Annual Meeting
Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases
Veronica Mruk¹, Kristine Carandang ², Megan Clowse ³, Stacy Ardoin ⁴, Elise Berlan ⁵ and Cuoghi Edens ⁶, ¹Nationwide Children's Hospital / The Ohio State University, Columbus, OH, ²University of California/Child and Adolescent Services Research Center, San Diego, CA, ³Duke University, Durham, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hosptial / The Ohio State University, Columbus, OH, ⁶University of Chicago, Chicago, IL
Background/Purpose: The diagnosis of a pediatric rheumatic disease comes with worries for both parents and patient; one that may be overlooked is the impact on…
Abstract Number: 2240 • 2019 ACR/ARP Annual Meeting
Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis
Chanakya Sharma¹, Samuel Whittle ², Pari Delir Haghighi ³, Frada Burstein ³, Roee Sa'adon ⁴ and Helen Keen ¹, ¹Fiona Stanley Hospital, Perth, Australia, ²The Queen Elizabeth Hospital, Adelaide, Australia, ³Monash University, Melbourne, Australia, ⁴Treato, Or Yehuda, Israel
Background/Purpose: Our hypothesis is that patients have a positive opinion regarding the newer, biologic DMARDs and a negative sentiment towards the conventional synthetic agents. We…
Abstract Number: 2241 • 2019 ACR/ARP Annual Meeting
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Kaveh Ardalan¹, Oluwatosin Adeyemi ², Dawn Wahezi ³, Anne Caliendo ⁴, Megan L. Curran ⁵, Jessica Neely ⁶, Susan Kim ⁶, Colleen Correll ⁷, Emily Brunner ⁸ and Andrea Knight ⁹, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, ²Children's Hospital of Philadelphia, Philadelphia, ³Children’s Hospital at Montefiore, New York, ⁴Northwestern University Feinberg School of Medicine, Chicago, ⁵University of Colorado, Aurora, CO, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Minnesota, Minneapolis, ⁸Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: While juvenile myositis (JM) can negatively affect quality of life, studies of the emotional health needs of youth with JM are limited. We examined…
Abstract Number: 2242 • 2019 ACR/ARP Annual Meeting
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Sarah Ahmed¹, Srita Chakka ², Rebecca Krain ³, Rui Feng ⁴ and Victoria Werth ⁵, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: The FDA uses near or total clearance in cutaneous disease in inflammatory skin conditions as an endpoint in clinical trials. However, patients may experience…
Abstract Number: 2243 • 2019 ACR/ARP Annual Meeting
Knowledge, Needs and Expectations Among Systemic Lupus Erythematosus: Preliminary Results from the INTEGRATE Pilot Project
Valentina Lorenzoni¹, Ilaria Palla ², Elena Elefante ³, Chiara Tani ³, Sara Cannizzo ², Salvatore Pirri ², Isotta Triulzi ², Leopoldo Trieste ², Gamal Chehab ⁴, Jutta Richter ⁴, Anna Kernder ⁵, Matthias Schneider ⁶, Giuseppe Turchetti ², Marta Mosca ³ and Patients' representatives on behalf of LUPUS EUROPE ⁷, ¹Institute of Management , Scuola Superiore Sant'Anna, Pisa, Italy, ²Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ⁵Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁷LUPUS EUROPE, Belgium, Belgium
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease characterized by multi-organ involvement and a complex clinical picture, with a wide range of manifestations…
Abstract Number: 2244 • 2019 ACR/ARP Annual Meeting
What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Thomas Schnitzer¹, Rebecca Robinson ², Lars Viktrup ², Joseph Cappelleri ³, Andrew Bushmakin ³, Leslie Tive ⁴, Jennifer Mellor ⁵, Nathan Williams ⁵, Pavlina Hubanova ⁵ and James Jackson ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Eli Lilly and Company, Indianapolis, IN, ³Pfizer Inc, Groton, CT, ⁴Pfizer, Inc, New york, NY, ⁵Adelphi Real World, Bollington, England, United Kingdom
Background/Purpose: To describe patterns of care and physician satisfaction with prescribed treatments for osteoarthritis (OA).Methods: Data were collected from February-May 2017 using US Adelphi Disease…
Abstract Number: 2245 • 2019 ACR/ARP Annual Meeting
Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Lisa Christopher-Stine¹, William Kelly ², George Wan ³, Linda Kobert ⁴ and Michael Reed ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Myositis Center, Baltimore, MD, ³Mallinckrodt Pharmaceuticals, Bedminster, NJ, ⁴The Myositis Association, Alexandria, VA, ⁵Vedanta Research, Chapel Hill, NC
Background/Purpose: Flare activity or worsening symptoms are not well defined for myositis. This analysis characterizes PM and DM flares from the patient perspective and reports…
Abstract Number: 2246 • 2019 ACR/ARP Annual Meeting
Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Kaleb Michaud ¹, Evo Alemao ², Miroslawa Nowak ³, Rachel Bruce ⁴, Sarah Cantor ⁴, Carlijn Hintzen ⁵, Philip Mease ⁶, Kendra DeBusk² and Alexis Ogdie ⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴IQVIA, New York, ⁵IQVIA, Amsterdam, Netherlands, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁷University of Pennsylvania, Philadelphia
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease resulting in significant symptom burden.1 Over time and without adequate treatment, PsA can lead to disability…
Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Raj Vachhani¹, Lang Chen ¹, Ronan O'Beirne ², Joshua Melnick ³, Eric Ruderman ⁴, Jeffrey Curtis ¹ and Maria Danila ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…
Abstract Number: 2248 • 2019 ACR/ARP Annual Meeting
Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease
Kelly Gavigan¹, Shilpa Venkatachalam ¹, Jeffrey Curtis ², Carole Wiedmeyer ¹, Tien Sydnor-Campbell ¹, Christine Stake ¹, Terri Robinson ¹ and W. Benjamin Nowell ¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: While there have been significant improvements in quality of life among people living with rheumatic and musculoskeletal disease (RMD) with the introduction of biologics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].